|5.05 -0.44 (-8.01%)||12-07 16:00|
|Targets||6-month :||7.85||1-year :||11.51|
|Resists||First :||6.72||Second :||9.85|
|Supports||First :||1.64||Second :||1.37|
|MAs||MA(5) :||3.32||MA(20) :||2.2|
|MA(100) :||2.12||MA(250) :||2.57|
|MACD||MACD :||0.5||Signal :||0.1|
|%K %D||K(14,3) :||56.4||D(3) :||63.1|
|52-week||High :||9.85||Low :||1.1|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SERA ] has closed above the upper band by 8.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 570.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||5.67 - 5.7||5.7 - 5.72|
|Low:||4.65 - 4.68||4.68 - 4.7|
|Close:||5 - 5.05||5.05 - 5.09|
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Diagnostics & Research
|Shares Out||0 (M)|
|Shares Float||30 (M)|
|Held by Insiders||2.019e+007 (%)|
|Held by Institutions||15 (%)|
|Shares Short||237 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-19 %|
|Return on Assets (ttm)||485.7 %|
|Return on Equity (ttm)||-24.8 %|
|Qtrly Rev. Growth||330000 %|
|Gross Profit (p.s.)||-178.28|
|Sales Per Share||-143.8|
|Qtrly Earnings Growth||-1.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-28 (M)|
|Price to Book value||0|
|Price to Sales||-0.04|
|Price to Cash Flow||0.6|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|